bpc-157 cas 137525-51-0 pubchem (10 MG) BPC-157 Peptide (Body Protection Compound)

Monitoring and Follow-up Clinical monitoring during BPC-157 treatment should include both safety parameters and therapeutic outcome measures

[DOI] [PMC free article] [PubMed] [Google Scholar] 8.Yoshikawa T, Hayashi N, Yamamoto S, Tajiri Y, Yoshioka N, Masumoto T, Mori H, Abe O, Aoki S, Ohtomo K

J Clin Hypertens (Greenwich) 2019;21(12):1879-1894

The concentrations of VB9 and VB2 in ASD group were lower, while the concentrations of VB12 were higher than those in HC group (although not significant)

The treatment takes just a few minutes and requires no recovery time

The discrepancy between our study and theirs might be related to a lower sample size that precluded them for obtaining statistical significance, and/or to the presence of CIS patients in the study cohort in which, disability was low, and if existent, the underlying mechanisms of progression that determine an increase in CSF biomarkers of advanced disease, such as CHI3L1, might also be underrepresented